Send to

Choose Destination
Br J Dermatol. 2010 Oct;163(4):781-8. doi: 10.1111/j.1365-2133.2010.09915.x. Epub 2010 Sep 2.

Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?

Author information

Department of Dermatology, Bispebjerg Hospital, Bispebjerg bakke 23, Copenhagen 2400, Denmark.



The oncogenic potential of deregulated Notch signalling has been described in several haematopoietic malignancies. We have previously reported an increased expression of Notch1 in primary cutaneous CD30+ lymphoproliferative disorders, lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma (pcALCL).


To investigate the functional importance of Notch signalling in cell lines derived from pcALCL.


Cell lines derived from pcALCL (Mac1, Mac2a and JK) were treated with different γ-secretase inhibitors (GSIs) (GSI I, IX, XX and XXI). The effects of GSIs on cell viability, apoptosis and cell cycle progression were measured as well as the impact of GSI I on the known prosurvival pathway Akt-mTOR-FOXO3a.


Notch family members were expressed in all investigated pcALCL cell lines. GSI I had a marked proapoptotic effect, but GSI IX, XX and XXI were much less potent. The GSI I-triggered apoptosis was preceded by an accumulation of cells in the G2/M, cyclin B1-controlled phase of the cell cycle accompanied by an increase in the cyclin-dependent kinase inhibitor, p21(WAF/Cip) . GSI I induced the nuclear translocation of proapoptotic FOXO3a, probably via an Akt-independent pathway.


Notch signalling may be a future therapeutic target for the treatment of advanced pcALCL.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center